
Opinion|Videos|March 10, 2025
Molecular Monitoring Advances in PV Disease Assessment and Management
Author(s)Prithviraj Bose, MD
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please explain how advances in JAK2 V617Fand other molecular monitoring have enhanced your ability to assess disease progression and guide initial treatment decisions for your patients with PV.
Advertisement
Related to this article

The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.

The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.

Andrew Aguirre, MD, PhD, explained how daraxonrasib, a molecular glue RAS inhibitor, nearly doubled overall survival in previously treated pancreatic cancer.

Final PECATI results show a median PFS of 22.1 months and median OS of 40.2 months with lenvatinib plus pembrolizumab in pretreated B3 thymoma and thymic carcinoma.

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
3
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
4
FDA Fast Tracks Onvansertib for First-Line RAS-Mutated mCRC
5
